Press Release - TB-PRACTECAL, a clinical trial led by Doctors Without Borders (MSF) has found that a new all-oral six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the currently accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB who currently face lengthy treatment regimens of up to 20 months that can include painful injections and up to 20 pills a day that can cause severe side-effects.
